Prognostic significance of ischemia-modified albumin in patients with acute coronary syndrome

Basit Öğe Kaydı
dc.authorid0000-0002-5634-1280en_US
dc.authorid0000-0003-1407-5313en_US
dc.contributor.authorAparcı, Mustafa
dc.contributor.authorKardeşoğlu, Ejder
dc.contributor.authorÖzmen, Namık
dc.contributor.authorÖzcan, Ömer
dc.contributor.authorCebeci, Bekir Sıtkı
dc.contributor.authorDinçtürk, Mehmet
dc.date.accessioned2024-07-12T21:03:06Z
dc.date.available2024-07-12T21:03:06Z
dc.date.issued2007en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractTo improve prognosis in acute coronary syndrome, new clinical applications in terms of diagnosis, risk stratification, and treatment strategies are still under investigation. Ischemia-modified albumin was one of the novel markers of myocardial ischemia. In our study, we aimed to determine the prognostic significance of the albumin cobalt binding capacity test in patients with acute coronary syndromes. We compared the ischemia-modified albumin levels of patients with acute coronary syndrome with those of patients with stable coronary artery disease and those of normal individuals and found them to be significantly higher in the first group (P<0.05). A cutoff value of ischemia-modified albumin of 477 U/ml was found by using receiver operating characteristic curve analysis. Mortality in groups of patients whose ischemia-modified albumin levels were above 477 U (50%) was found to be significantly higher than in those whose levels were below 477 U (8.3%) (P<0.05). The sensitivity and specificity of the cutoff value, 477 U/ml, for the 1-year mortality were found to be 70 and 82%, respectively. Using the Cox regression model the relation of albumin cobalt binding capacity test results with mortality was statistically significant (beta=1.013, confidence interval 95%, P=0.01) and independent of the existence of hypertension, diabetes, and advanced age. In conclusion, ischemia-modified albumin was found to be significantly related to 1-year mortality. Prognostic significance of ischemia-modified albumin should be evaluated in large populated and randomized study groups. Afterwards, ischemia-modified albumin could be used in risk stratification modality in patients with acute coronary syndrome.en_US
dc.identifier.citationAparci, M., Kardesoglu, E., Ozmen, N., Ozcan, O., Cebeci, B. S., Cingozbay, B. Y. ve Dincturk, M. (2007). Prognostic significance of ischemia-modified albumin in patients with acute coronary syndrome. Coronary artery disease, Wolters Kluwer Health. 18(5), s. 367–373.en_US
dc.identifier.endpage373en_US
dc.identifier.issn0954-6928
dc.identifier.issn1473-5830
dc.identifier.issue5en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage367en_US
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/17627186/
dc.identifier.urihttps://hdl.handle.net/20.500.12415/3630
dc.identifier.volume18en_US
dc.institutionauthorCingözbay, Bekir Yılmaz
dc.language.isoenen_US
dc.publisherWolters Kluwer Healthen_US
dc.relation.ispartofCoronary Artery Diseaseen_US
dc.relation.isversionof10.1097/MCA.0b013e3281689a50en_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsCC0 1.0 Universal*
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/*
dc.snmzKY00565
dc.subjectacute coronary syndromeen_US
dc.subjectischemia-modified albuminen_US
dc.subjectmortalityen_US
dc.subjectprognosisen_US
dc.titlePrognostic significance of ischemia-modified albumin in patients with acute coronary syndromeen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu